Full-Time

Cardiovascular Specialist

Health and Science Professional

Posted on 8/17/2026

Deadline 9/2/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$76k - $199.6k/yr

No H1B Sponsorship

Buffalo, NY, USA + 1 more

More locations: New York, NY, USA

Hybrid

Must live within 25 miles of the territory border; residence within the territory is preferred.

Bachelor's, Associate's

Category
Sales & Account Management (1)
Required Skills
Sales
CRM
Marketing
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A Bachelor's Degree, or an associate's degree with 6+ years of relevant experience, or a high school diploma or equivalent with 8+ years of relevant experience.
  • At least 2 years of experience in professional sales or promotional activity; small business ownership or entrepreneurial experience; marketing, customer service, or account management; relevant healthcare or scientific roles; education; or full-time military experience.
  • Must live within 25 miles of the border of the assigned territory.
  • A valid United States driver's license and driving record compliant with company standards are required; any DUI/DWI or other impaired-driving citation within the past 7 years disqualifies the candidate.
  • Candidates must be authorized to be employed in the United States by any employer and must have permanent United States work authorization.
Responsibilities
  • Drive sales in the assigned territory.
  • Engage with customers face to face and virtually.
  • Develop and implement effective business and territory call plans and live or virtual customer-engagement strategies.
  • Build rapport and relationships with customers in live and virtual environments while using digital tools to maintain customer engagement.
  • Use internal reports and analytics to identify, develop, and implement strategic business opportunities.
  • Use product and disease-state knowledge to compliantly educate providers on unbranded and branded product value propositions for relevant patient populations and approved clinically oriented disease-state information and patient resources.
  • Collaborate effectively and compliantly across the organization to address customer inquiries and advance Pfizer objectives.
  • Complete all administrative expectations on time and compliantly.
Desired Qualifications
  • One year of pharmaceutical, biotechnology, medical sales, or medical-related marketing experience.
  • A strong track record of sales or marketing success, territory-management skills, communication skills, teamwork, leadership ability, and accountability.
  • Experience with applicable disease states, therapeutic areas, and products.
  • Knowledge of territory customers and markets, including prescribers, healthcare professionals, institutions, and organizations.
  • Residence within the territory boundaries.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $15.0 billion; Pfizer raised 2026 guidance to $60.5–$62.5 billion.
  • FDA priority review for TALZENNA plus XTANDI targets a Q4 2026 prostate decision.
  • EMA validated Pfizer-Valneva Lyme vaccine filing, and Québec added PREVNAR 20 in May 2026.

What critics are saying

  • Eliquis faces patent expiry by decade-end, exposing Pfizer's largest growth engine to generics.
  • Sanofi sued Pfizer on July 15, 2026 over COVID vaccine patents, extending mRNA litigation.
  • $2.5 billion in new savings implies repeated restructuring through 2029 and fresh layoffs.

What makes Pfizer unique

  • Pfizer pairs global scale with hospital, vaccine, oncology, and biosimilar commercialization.
  • Seagen integration strengthened oncology, while PADCEV and TALZENNA expand late-stage franchises.
  • Lyme vaccine candidate and PREVNAR 20 show pipeline depth beyond COVID dependence.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.

Yahoo Finance
Aug 18th, 2026
Two profitable stocks with solid fundamentals and one to ignore

Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.

Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

Yahoo Finance
Aug 10th, 2026
Pfizer's earnings fall 58%, but dividend appears safe for now

Pfizer reported a 58% decline in net income for the first half of 2024, falling to $2.4 billion from $5.9 billion year-over-year. The decline was largely driven by $3.8 billion in non-cash impairment charges related to in-process research and development assets. Despite the earnings drop, the dividend appears sustainable. Over the past four quarters, Pfizer generated $11 billion in free cash flow, exceeding the approximately $9.8 billion paid in dividends. The company has struggled with growth whilst managing restructuring costs and integrating recent acquisitions. Its second quarter ended 30 June with a $248 million net loss. Pfizer's stock has fallen 44% over five years, though it's up 9% year-to-date. The dividend currently yields 6.4%.